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ABSTRACT  12 
The plastic monomer bisphenol A (BPA) is one of the highest production volume chemicals in the 13 
world and is frequently detected in wildlife and humans, particularly children. BPA has been 14 
associated with numerous adverse health outcomes relating to its estrogenic and other hormonal 15 
properties, but direct causal links are unclear in humans and animal models. Here we simulated 16 
measured (1) and predicted worst-case (10) maximum foetal exposures for BPA, or equivalent 17 
 2 
concentrations of its metabolite MBP, using fluorescent reporter embryo-larval zebrafish, capable 18 
of quantifying Estrogen Response Element (ERE) activation throughout the body. Heart valves 19 
were primary sites for ERE activation by BPA and MBP, and transcriptomic analysis of micro-20 
dissected heart tissues showed that both chemicals targeted several molecular pathways 21 
constituting biomarkers for calcific aortic valve disease (CAVD), including extra-cellular matrix 22 
(ECM) alteration. ECM collagen deficiency and impact on heart valve structural integrity were 23 
confirmed by histopathology for high-level MBP exposure, and structural defects (abnormal 24 
curvature) of the atrio-ventricular valves corresponded with impaired cardiovascular function 25 
(reduced ventricular beat rate and blood flow). Our results are the first to demonstrate plausible 26 
mechanistic links between ERE activation in the heart valves by BPA’s reactive metabolite MBP 27 
and the development of valvular-cardiovascular disease states. 28 
INTRODUCTION  29 
Over 1400 chemicals have been identified as potential endocrine disrupting chemicals (EDCs) (1) 30 
with potential to “alter function(s) of the endocrine system and consequently cause adverse health 31 
effects in an intact organism, or its progeny, or (sub)populations” (2-5).  Over 100 of these 32 
chemicals are regarded internationally as priority EDCs and almost half (45%) are estrogenic i.e. 33 
estrogen receptor (ER) and/or estrogen-related receptor (ERR) agonists (6-8).  Estrogens play a 34 
fundamental role in the formation and function of numerous organs and systems (9) and 35 
imbalances are known to increase risks of cancers and disorders of reproductive, nervous, 36 
metabolic, immune and cardiovascular systems in various animal models and humans (10-14).  37 
However, linking cause and effect remains a major challenge in chemical risk/safety assessment.  38 
Bisphenol A (BPA) is associated with the above disorders and is one of the world’s highest 39 
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production volume chemicals (15), to which humans are continually exposed via plastic and other 40 
products (16-23).  Reported BPA-effect mechanisms include agonism of nuclear ERs (24), ERRs 41 
(25,26), membrane ERs (27,28), epigenetic modulation of estrogen response elements (EREs) 42 
(29,30) and weak agonism of androgen and thyroid (T3) receptors (31,32).  Over 2700 peer-43 
reviewed papers have been published on the endocrine effects of BPA (Scopus search, September 44 
2018) illustrating the level of scientific interest in BPA.  Despite this high number of studies, 10% 45 
of which are in vivo studies, regulatory authorities have concluded that there is insufficient 46 
evidence to establish causal links between BPA and adverse effects on human health (21,33,34).  47 
Nevertheless, public pressure has prompted the removal of BPA from baby products in Canada, 48 
Europe and North America (35,36), due to higher exposures and lower competence for 49 
metabolising BPA in infants (17,37).  Some of the replacement products for BPA are also 50 
estrogenic in mammals (38) and fish (39).  Furthermore, the reactive BPA metabolite 4-methyl-51 
2,4-bis(p-hydroxyphenyl)pent-1-ene (MBP) has been shown to be far more potent than the parent 52 
BPA in terms of: estrogen receptor binding and activation in vitro (10-1000) (40); stimulation of 53 
uterine growth in rats (500) (41); elevated estrogen receptor (esr1) and vitellogenin (vtg1, vtg2) 54 
gene and protein expression in medaka (Oryzias latipes) (250-400) (42,43); ERE activation in 55 
zebrafish (Danio rerio) (1000) via esr1 (44).  These findings indicate an urgent need for more 56 
integrative test systems capable of evaluating multiple effect levels, linking key molecular events 57 
and adverse outcomes for chemicals like BPA and its analogues and metabolites.  58 
Transgenic (TG) zebrafish models offer suitable integrative test systems, whereby key molecular 59 
events (e.g. (ant)agonism of hormone receptors, or hormone metabolism) can be identified and 60 
quantified by fluorescent protein reporters linked to specific enzymes, receptors or response 61 
elements (45).  Spatial and temporal resolution of key molecular events in TG zebrafish can 62 
 4 
facilitate the detection of chemical effects throughout the body in vivo, in real time (45-49) and 63 
can help establish causal links with subsequent adverse effects on biological development and/or 64 
function (39,44).  Here we exploit TG(ERE:GFP)Casper zebrafish to study the effects of BPA and 65 
its highly estrogenic metabolite MBP on cardiovascular (CV) development and function, building 66 
on previous work using this model, which highlighted the heart, and heart valves in particular, as 67 
being key targets for these compounds (39,44,47,48).   68 
 69 
MATERIALS AND METHODS 70 
Test substances  71 
Bisphenol A or BPA: 2,2-bis(4-hydroxyphenyl)propane (99% pure, CAS No. 80-05-7) was 72 
obtained from Sigma-Aldrich Company Ltd., Dorset, UK.   73 
The BPA derivative MBP: 4-methyl-2,4-bis(p-hydroxyphenyl)pent-1-ene (99% pure, CAS No. 74 
13464-24-9) was synthesised at the University of Exeter (SI (Figure S1).   75 
 76 
Test organisms 77 
Test organisms were 3rd generation homozygous TG(ERE:GFP)Casper zebrafish (Danio rerio) 78 
(48), combining a green fluorescent protein (GFP) reporter system for estrogen response element 79 
(ERE) activation (45) in a translucent Casper phenotype (50).  This translucent model extends the 80 
use of fluorescent reporters to life-stages >5 dpf, which would otherwise gain skin pigmentation 81 
that interferes with GFP detection (48).  This is an important feature of the model, as EDC effects 82 
may vary both within a tissue and between body tissues at different life-stages (4,51,52).  The life-83 
stages selected for this study represent two key landmarks in CV development: 5 days post 84 
fertilisation (dpf) marking formation of the endocardial rings (precursors to the heart valve 85 
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leaflets); 15 dpf marking elongation of the valve leaflets (53-55).  The latter life-stage also 86 
corresponds with the depletion of the egg yolk and peaks in metabolism (oxygen consumption) 87 
and heart beat rate (56).  88 
The zebrafish is an established model for biomedical research on CV development, function and 89 
disease (53,55,57), including heart valve (mal)formation (58-61).  Despite some basic anatomical 90 
differences from the human heart (58,62), the cellular and molecular mechanisms of heart 91 
development are highly conserved between zebrafish and humans (55,63) and zebrafish have 92 
several major advantages over other vertebrate models.  Heart formation (including valvulogenesis 93 
and remodelling, outlined in detail in Supporting Information SI Table S1) is completed by 35 dpf 94 
(62,63), but a heartbeat is detectable as early as 1 dpf, with blood circulation beginning soon 95 
thereafter (64).  Standard (resting) heart beat rate in 5-15 dpf embryo-larval zebrafish (160–260 96 
beats per minute; bpm) is much closer to resting human foetal heart rate (130–170 bpm) than in 97 
rodents (300–600 bpm) (56,65-67).  Furthermore, respiration in embryo-larval stages relies mainly 98 
on cutaneous diffusion of O2 and CO2, rather than transport by convective blood circulation (68), 99 
enabling the in vivo study of late phenotypes of congenital CV malformations, which would be 100 
lethal in mammals (57).   101 
 102 
Ethical statement 103 
All experimental procedures with zebrafish were conducted in accordance with UK Home Office 104 
regulations for the use of animals in scientific procedures and followed local ethical review 105 
guidelines and approval processes. Water quality was assessed daily (SI Table S2). 106 
 107 
Chemical exposure  108 
 6 
TG zebrafish embryos/larvae were exposed in the laboratory from 6 hours post fertilisation (hpf) 109 
to 5 days post fertilisation (dpf) or from 6 hpf to 15 dpf, to aqueous concentrations of BPA (solvent 110 
(0.5% DMSO) control 0; low 100; high 1000 µg/L) or its metabolite MBP (solvent control 0; low 111 
2.5; high 25 µg/L) in glass 1L aquaria (n=6 aquaria per exposure treatment), positioned in random 112 
order and each containing ~120 randomly assigned embryos.  The lower BPA concentration was 113 
expected to represent maximum measured human maternal-foetal-placental unit concentrations of 114 
up to 105 ng/g (69,70), based on bioconcentration factors ranging from 0.25 to 5.7 in larval and 115 
adult zebrafish (39,71,72).  Both lower and 10× higher (worst case) BPA concentrations were 116 
substantially below maximum tolerable concentrations (48).  MBP exposure concentrations were 117 
based on a relative potency of 250× compared to BPA, measured in vivo in juvenile medaka (43).  118 
Stock solutions were prepared by dissolving pure test chemicals in analytical grade dimethyl 119 
sulfoxide (DMSO) and then diluting (200×) in 400 mL of embryo culture water (73) to give the 120 
desired nominal exposure concentrations in 0.5% DMSO.  The pH of stock solutions was checked 121 
and adjusted to 7.5, as necessary.  For the longer-term (0-15 dpf) exposure, 90% water changes 122 
were undertaken every 2 days, after commencing feeding twice a day at 6 dpf with excess <100 123 
µm particulate fish food (ZM000) and with Artemia salinus nauplii from 10 dpf.  Exposure 124 
solutions were maintained at 28°C, under a 16h:8h light : dark photoperiod cycle with a 15 min 125 
dawn/dusk transition.   126 
Concentrations of exposure solutions were measured in three replicate aquaria per exposure 127 
treatment at the start and end of each exposure period.  Chemical body burden was also measured 128 
in whole zebrafish embryo-larvae at 5 dpf, and in composite samples of 30 hearts extracted from 129 
5 dpf embryos (n=3 composite samples per treatment).  Heart extraction was performed en masse: 130 
50 larvae per aquarium were disrupted in ice-cold Leibovitz’s L-15 Medium (Invitrogen, UK) 131 
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containing 10% foetal bovine serum, using a 6 ml syringe and 19 gauge needle (74), and 30 hearts 132 
were isolated using a 30 µm mesh sieve followed by manual sorting in ice-cold Leibovitz’s L-15 133 
Medium under a 5× objective on an Olympus SZX16 microscope (Olympus, UK).  Fish/hearts 134 
were placed in embryo culture water with a terminal dose of anaesthetic of 2 mg/mL tricaine 135 
methanesulfonate (MS222) at pH 7.5, then dried under vacuum, macerated and extracted in a 136 
solution of 80:20 water:acetonitrile containing an internal standard.  Details of chromatographic 137 
separation and mass spectrometry analysis of BPA and MBP in water and fish tissues are provided 138 
in the SI (Table S3).  The limit of quantitation (LOQ) was 0.05 µg BPA/L and 0.05 µg MBP/L for 139 
water, and 0.5 ng BPA/g and 0.5 ng MBP/g for fish tissue.  Bioconcentration factors (BCFwhole body 140 
and BCFheart) were calculated based on a mean whole body wet weight of 1200 µg for 5 dpf 141 
zebrafish larvae and a ventricle weight of 10% of the whole body weight at 5 dpf (75). 142 
Following chemical exposure, TG zebrafish larvae were selected randomly from each aquarium 143 
and were subject to the following effects analyses, which were conducted at 28°C.  144 
 145 
Quantifying ERE activation (estrogenicity) 146 
ERE activation was quantified in the atrio-ventricular (AV) and ventricular-bulbus (VB) valves as 147 
follows.  At 5 and 15 dpf 6 larvae per replicate aquaria (n=6) were washed and then anaesthetised 148 
in 0.1 mg/mL MS222 at pH 7.5 and mounted in vivo in 1% low melting agarose in embryo culture 149 
water with MS222, and then placed into a glass bottom 35 mm dish (MatTek, Ashland, MA, USA).  150 
Larvae were orientated right side down and images were obtained using an inverted compound 151 
microscope (Zeiss Axio Observer, Cambridge, UK) with a 10× objective, under consistent GFP 152 
excitation for a scanning time of 180 ms, using filter set 38 HE: Excitation BP 470/40 nm, Beam 153 
splitter FT 495 nm, Emission BP 525/50 nm.  GFP expression was quantified as the relative mean 154 
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pixel intensity of green fluorescence (relative to the solvent control) in a defined region of interest 155 
(ROI) encompassing the heart, using ImageJ software (76).   156 
 157 
Histopathology of the heart and heart valve leaflets 158 
Histopathology of the heart and heart valve leaflets was conducted on 6 whole zebrafish larvae 159 
per replicate aquaria (n=6) at 5 and 15 dpf, following terminal anaesthesia in 2 mg/mL MS222 at 160 
pH 7.5, and destruction of the brain.  For visible light microscopy, zebrafish were fixed in Bouin’s 161 
solution (Sigma Aldrich, Dorset, UK), progressively dehydrated in 70-100% industrial methylated 162 
spirits and embedded in paraffin wax.  For transmission electron microscopy (TEM), zebrafish 163 
were fixed in 2% glutaraldehyde and 2% paraformaldehyde in 0.1M PIPES buffer (pH 7.2) for 24 164 
h, washed with buffer (3  5 min) and post-fixed for 1 h in 1% osmium tetroxide (reduced with 165 
1.5% w/v potassium ferrocyanide) in 0.1M sodium cacodylate buffer (pH 7.2).  After a series of 166 
washes in deionised water (3  5 min) the larvae were subject to in-block staining with 1% uranyl 167 
acetate for 30 mins, then 3  5 min washes with deionised water and then the larvae were 168 
dehydrated through an ethanol gradient and embedded in Spurr resin (TAAB Laboratories, 169 
Aldermaston, UK).  Sagittal sections were obtained through the midline of the atrium and ventricle 170 
(to examine the AV valves).  For visible light microscopy, serial sections (5 μm) were obtained 171 
and placed on glass slides, stained using Masson’s trichrome and examined using a Leitz Diaplan 172 
light microscope [×(10-100) magnification] to assess for structural pathologies (focusing on 173 
valvular cells and interstitial extracellular matrix).  For TEM, 70 nm ultrathin sections were 174 
collected on pioloform-coated EM copper slot grids (Agar Scientific, Stansted, UK) and were 175 
analysed using a JEOL JEM 1400 operated at 120kV, and images taken [×(3000-20000) 176 
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magnification] with a digital camera (ES 100W CCD, Gatan, Abingdon, UK) to assess for any 177 
ultra-structural effects on the heart valves.  178 
 179 
Quantifying CV function 180 
Non-invasive video analysis of the heart and dorsal aorta was used to measure multiple 181 
cardiovascular (CV) endpoints simultaneously (67).  At 15 dpf 6 larvae per replicate aquaria 182 
(n=6), were anaesthetized in 0.1 mg/mL MS222 and embedded right side down in 1% agarose in 183 
a single well of a press-to-seal silicon isolator (Sigma-Aldrich, Poole, UK) on a clear microscope 184 
slide.  The slide was then viewed using an inverted light microscope (Leica DM IRB, Leica 185 
Microsystems UK Ltd., Milton Keynes, UK, 5× objective) fitted with two high speed video 186 
cameras.  The first camera (Grasshopper® GRAS-50S5C-C, Richmond, Canada) recorded 187 
ventricular heart beat at 30 frames per second (the atrium was obscured at 15 dpf).  The second 188 
camera recorded blood flow in the dorsal aorta, caudal to the swim bladder, at 120 frames per 189 
second (Grasshopper® GRAS-03K2M-C, Richmond, Canada).  Both cameras were focused 190 
independently on their respective regions of interest, to ensure optimal image quality, and set to 191 
record simultaneously for 5 min; recordings from the last 3 mins were subject to image analysis 192 
as follows.  Resting (standard) ventricular beat rate (bpm - beats per minute) was measured using 193 
MicroZebraLab™ image analysis software (v3.5, ViewPoint, Lyon, France).  Resting (standard) 194 
aortic blood flow rate (nL/s) was measured using ZebraBlood™ (v1.3.2, ViewPoint, Lyon, 195 
France).   196 
 197 
Quantifying metabolic scope  198 
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Metabolic scope, combining scope for growth and scope for movement, were measured in terms 199 
of specific growth rate (SGR) (77) and critical swimming speed (Ucrit) (78), respectively.  SGR 200 
was calculated by measuring individual standard body length [±0.01 mm from snout to caudal 201 
peduncle] of TG zebrafish larvae (10 per aquarium) under anaesthetic (0.1 mg/mL MS222) at 5 202 
and 15 dpf, using an Olympus SZX16 microscope and cellSensTM image analysis software.  Since 203 
individual fish were not tagged, mean specific growth rate (mean SGR as % standard body length 204 
per day) was calculated for each aquarium (Equation 1).  Critical swimming speed (Ucritb as 205 
standard body lengths/sec) was then assessed at 15 dpf, by placing 5 larvae at a time in a 206 
cylindrical swim flume of length 25 cm, internal diameter 2 cm and volume 78.55 mL, and 207 
increasing laminar water flow incrementally by 1.33 cm/sec every 300 secs (5 mins) until the time 208 
to exhaustion for all individual larvae.  Ucritb was calculated based on aquarium-mean standard 209 
body length at 15 dpf (Equation 2). 210 
Equations 211 
1) Mean SGR = ((ln SL @15 dpf) – ln SL @ 5 dpf) / T)*100 212 
Where SL is mean standard length per aquarium (mm); T is time interval (days)  213 
 214 
2) Ucritb = U + (t / ti * Ui)  215 
Where U is penultimate swimming speed (mean standard body lengths/sec); Ui is velocity 216 
increment (1.33 cm/sec); t is time swum in final velocity increment (secs); ti is time interval for 217 
each increment (300 secs). 218 
 219 
Transcriptomic profiling of heart tissues 220 
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Hearts were removed from TG zebrafish larvae following terminal anaesthesia in 2 mg/mL MS222 221 
at pH 7.5, followed by destruction of the brain.  At 5 dpf 50 larvae per replicate aquaria (n=4) 222 
were disrupted in ice-cold Leibovitz’s L-15 Medium (Invitrogen, UK) containing 10% foetal 223 
bovine serum, and hearts were extracted en masse, as described above.  Hearts from larvae of 15 224 
dpf were micro-dissected individually using fine tip forceps (Dumont Inox #5SF) and an Olympus 225 
SZX16 microscope.  Hearts for the 15 dpf larvae were pooled (30 per aquarium) and then snap 226 
frozen in liquid nitrogen.  Total mRNA was extracted from each pool of 30 hearts using RNeasy 227 
micro-kits with on-column DNase treatment (Qiagen, UK) and RNA integrity (RIN) scores were 228 
confirmed to be in the range 7.4-8.7 using an Agilent 2200 TapeStation (Agilent Technologies 229 
Ltd. Berkshire, UK).  cDNA libraries were prepared with polyA isolation using Illumina 230 
TruSeqTM 2 Stranded mRNA Library Preparation kits and subsequent cluster generation was 231 
conducted using TruSeqTM Paired-End Cluster Generation kits (Illumina, San Diego CA, USA).  232 
Up to 24 cDNA libraries were prepared for sequencing for each test substance (BPA and MBP): 233 
nominally n=4 replicate pooled samples from each of 3 treatment groups (solvent control, low, 234 
high exposure), for two time points (5 dpf and 15 dpf).  Libraries were sequenced with 12 per lane 235 
using an Illumina HiSeq 2500 in standard mode, generating 100 base pair reads (paired-end).   236 
 237 
Statistical analysis 238 
Prior to statistical analysis, phenotypic data were tested for normality (Anderson–Darling test) and 239 
homogeneity of variance (Bartlett's or Levene's tests) using Minitab 16 (Minitab, Coventry, UK).  240 
Statistical analysis of phenotypic/functional endpoints was performed using linear mixed effects 241 
(lme) models (R-statistics version 3.3.2, R Foundation for Statistical Computing) and all lme 242 
models included aquarium as a random effect.  A multi-variate MANOVA was used to assess the 243 
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fixed effect of exposure treatment on cardiovascular function, combining both ventricular heart 244 
beat rate and blood flow (using the function ‘cbind’).  Statistical significance (p<0.05)  of treatment 245 
effects on these and other individual phenotypic endpoints was also determined by ‘one-way’ 246 
comparisons of untransformed heart beat or blood flow data, and lme model fit was measured 247 
using the Akaike Information Criterion (AIC).  Phenotypic/functional effects data are presented in 248 
the text or shown graphically as the mean ± 95% confidence interval. 249 
Transcriptomic data were quality-trimmed and filtered (to remove sequencing adapters) and then 250 
processed using the TopHat/ Cufflinks pipeline (79), followed by differential gene expression 251 
analysis comparing chemical exposure treatments with control treatments using DESeq2 v3.6 and 252 
an adjusted p-value of <0.05 set as the false discovery rate (80).   253 
Gene Set Enrichment Analysis (GSEA) using DAVID v6.8 (81), Enrichr (82) and Reactome v66 254 
(83) was conducted on sets of differentially expressed genes (for each chemical exposure 255 
treatment) to identify over-represented Gene Ontology (GO) terms for biological processes and 256 
functional pathways, including KEGG v88 (84) and Reactome v66 pathways (83) referenced to 257 
the zebrafish (GRCz10) and the human genome (GRCh38.p12). 258 
Transcription Factor Binding Site (TFBS) motif enrichment analysis was conducted on 5 and 50 259 
kilobase (kB) long DNA flanking sequences both up and downstream of the differentially 260 
expressed genes to quantify the potential for estrogen receptor interactions; flanking sequences 261 
were retrieved using BioMart from Ensembl v94 (85). Over-represented motifs in each gene set 262 
were identified using AME (86) in MEME Suite v5.0.2 (http://meme.nbcr.net). Each gene set was 263 
‘shuffled’ to generate a control gene set (with matched GC content), and enriched TFBS motifs 264 
were subsequently identified using the JASPAR 2018 (CORE:vertebrate) database (87). 265 
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Gene groups were considered to be enriched when enrichment scores (EASE scores) were >1.3, 266 
and when p-values adjusted for multiple-testing (Benjamini-Hochberg) were < 0.1.  267 
 268 
RESULTS AND DISCUSSION 269 
 270 
Chemical exposure  271 
Mean measured concentrations of aqueous exposure solutions were 104-128% of nominal values 272 
for 100 and 1000 µg/L BPA (117 ± 4, 1028 ± 23 µg/L) and 82-113% of nominals for 2.5 and 25 273 
µg/L MBP (2.1 ± 0.1, 28.2 ± 0.35), and both sets of controls contained no measurable test chemical 274 
(SI Table S4).  Mean measured bioconcentration factors for BPA were: 5 day BCFwhole body = 2.5 275 
and 3.8 for 100 and 1000 µg/L BPA exposures, respectively, corresponding with whole body 276 
concentrations of ~250 and ~3700 ng/g, which are equivalent to ×2.5 and ×37 maximum human 277 
maternal-foetal-placental unit concentrations of 105 ng/g (69,70).  Mean measured 5 day BCFheart 278 
= 0.09 for the 1000 µg/L BPA exposure was substantially lower than the corresponding BCFwhole 279 
body.  The mean measured bioconcentration factor for MBP was: 5 day BCFwhole body = 27 for the 25 280 
µg/L MBP exposure, corresponding with a whole body concentration of 675 ng/g.  MBP was not 281 
detectable above the LOQ (0.5 ng/g) in heart tissue, so a 5 day BCFheart could not be determined.   282 
 283 
ERE activation 284 
Exposure to BPA or MBP induced fluorescence from the ERE:GFP reporter in the liver and in the 285 
region of interest (ROI) encompassing the heart, specifically in the atrio-ventricular (AV) and the 286 
ventricular-bulbus (VB) valves (Figure 1), which is consistent with previous studies (44,48).  287 
Higher fluorescence intensity in the heart/valves was not due to chemical partitioning, since heart 288 
 14 
tissue concentrations for BPA were more than an order of magnitude lower than in whole body 289 
tissue (and the water concentration).  Instead, greater ERE activation and fluorescence in the heart 290 
valves may be due to tissue-specific expression of different ERs and receptor sub-types.  Relative 291 
mean fluorescence intensity in the ROI (relative to the solvent control) increased with BPA 292 
exposure concentration (100 to 1000 µg/L) from 2.2 ± 0.3 to 31 ± 2 at 5 dpf, and showed a similar 293 
concentration-related response, increasing from 15.3 ± 1.1 to 26.9 ± 0.2, at 15 dpf.  There was a 294 
similar response pattern in relative mean fluorescence intensity in the ROI for MBP, increasing 295 
with MBP exposure (2.5 to 25 µg/L) from 39 ± 3 to 54 ± 3 at 5 dpf, and from 3.0 ± 0.4 to 14.6 ± 296 
1.5 at 15 dpf (SI Figure S2).  Comparing relative mean fluorescence of MBP versus BPA for the 297 
lower-level exposure treatments, which can be assumed to lie on the linear sections of the dose 298 
response curves (44,48), we calculated the relative potency of MBP compared to BPA to be 710× 299 
at 5 dpf and 23× at 15 dpf (SI Table S5), which is consistent with results from previous in vivo 300 
studies on zebrafish (39,44), medaka (42,43) and rats (41).   301 
Greater potency of MBP compared with BPA may be explained, at least in part, by the 302 
bioconcentration of MBP from water (5 day BCFwhole body = 27), which was one order of magnitude 303 
greater than for BPA.  Chemical exposure level- and time- related changes in ERE/GFP expression 304 
in zebrafish heart valves are likely to be influenced by range of interacting factors.  The lower 305 
relative potency of MBP in larvae at 15 dpf, compared with that in 5dpf larvae, followed a net 306 
reduction in ERE:GFP fluorescence intensity, possibly corresponding (to some extent) with tissue 307 
thickening in older fish.  Furthermore, the reduction in fluorescence intensity over time was greater 308 
in MBP compared to BPA treatments.  These results are consistent with metabolic activation of 309 
BPA in fish (42,43,88) and greater metabolic activity in 15 dpf compared to 5 dpf zebrafish larvae 310 
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(56).  The observed variation in levels of ERE activation at these different life stages may also be 311 
due in part to age-related variation in the expression of different ERs and receptor sub-types (52). 312 
 313 
Effects on the structure of the heart valve leaflets 314 
There was qualitative evidence of ultra-structural changes in the AV valve leaflets in both BPA 315 
and MBP high-level exposure treatments at 15 dpf.  TEM images (3000-20000 magnification) 316 
showed the dislocation of valvular cells and the loss of collagen filaments from the interstitial 317 
extra-cellular spaces (Figure 2).  In the high-level MBP exposure there were also gross-structural 318 
changes in the AV valve leaflets.  Light microscopy images (100 magnification), taken following 319 
Masson’s trichromatic staining, showed that valve leaflets were misshapen (bent) and that the 320 
extra-cellular matrix between the bilayer of valvular cells was narrower and lacked collagen 321 
(indicated by the lack of blue stain) compared to solvent controls (Figure 2).  Although these ultra- 322 
and gross- structural effects were clearly evident, they could not be quantified morphometrically, 323 
due to the limited number (n=2 or 3 per treatment) of sagittal sections in which the AV valve 324 
leaflets were discernible.  No other heart valve pathologies were detected in any other treatment 325 
or time point, and there was no evidence of edema to indicate general cardiotoxicity.  Histological 326 
assessment of ventricular-bulbus (VB) valves was not possible from the sagittal sections taken to 327 
assess the AV valves, due to their alternative orientation/alignment. 328 
 329 
Effects on CV function 330 
There were no discernible effects of BPA exposure on CV function in agreement with a previous 331 
study (44), but high-level MBP exposure resulted in a statistically significant reduction (versus 332 
solvent controls) in ventricular heart beat rate (218 ± 4 versus 249 ± 7 bpm; p = 0.023) and aortic 333 
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blood flow rate (1.55 ± 0.07 versus 1.95 ± 0.06 nL/s; p = 0.03) in 15 dpf zebrafish, according to 334 
the linear mixed effect model lme(Rate ~ Treatment, random=~1|Tank1) (Figure 3; SI Table S6).  335 
These results fall within ranges reported at 28°C for zebrafish aged 3.5 to 21 dpf for resting heart 336 
beat rate (160 to 260 bpm) (56,65-67) and resting blood flow rate (500 to 1860 µm/s; equivalent 337 
to 0.25 to 2.1 nL/s) (67,89,90).  Ontogeny of embryo-larval development in zebrafish is such that 338 
heart beat and blood flow rate vary substantially with development time and peak at 10–20 dpf, a 339 
period which corresponds with a peak in aerobic metabolism (56).  Therefore CV performance is 340 
likely to be most critical for our selected life-stage (15 dpf) and reduced CV performance (20% 341 
reduction in blood flow rate) could be biologically significant.  The proportional reduction in blood 342 
flow (20  3.6%) was greater than for heart beat rate (12  2.3%), potentially indicating valve 343 
prolapse (although note the variation in these CV parameters).  We were unable to observe valve 344 
function directly because of tissue thickening, nor were we able to demonstrate AV decoupling as 345 
being symptomatic of valve prolapse (91), since organ growth prevented imaging of both atrial 346 
and ventricular beating at 15 dpf.  Nevertheless BPA exposures up to 2500 μg/L have been shown 347 
to induce erratic AV beat ratios in 5 dpf zebrafish (44). 348 
 349 
Effects on metabolic scope 350 
No effects of BPA or MBP were seen on metabolic scope (i.e. SGR and Ucritb) (SI Figure S3 and 351 
Table S7).  These energetic measures provide a general indication of individual metabolic scope, 352 
i.e. energetic reserves beyond basal metabolism (92).  Ucritb integrates anaerobic as well as aerobic 353 
scope for movement (93) and also cardio-respiratory performance (65).  The lack of significant 354 
effects (despite downward trends for MBP) may have been due to substantial inter-individual 355 
variation across the exposure treatments.  Inter-individual differences in locomotory performance 356 
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traits have been observed in larval zebrafish between 3 to 21 dpf, and shown to be due to heritable 357 
genetic factors not necessarily related to body size (65).  Our test organisms were 3rd generation 358 
transgenic zebrafish maintained in up to six spawning groups with 30 fish in each group, therefore 359 
genetic variation may have been a confounding factor, but this was not quantified.  High inter-360 
individual variation may also be related to larval swimming behaviour, which is characterized by 361 
intermittent bursts of swimming (94), such that prolonged swim challenge tests >10 mins may not 362 
reliably indicate swimming stamina (65).  Our swim challenge tests typically ran for 5-10 mins 363 
and mean Ucritb ranged from 10.7 to 12.6 body lengths/sec, which is comparable to values reported 364 
elsewhere, ranging from 13 to 18 body lengths/sec in juvenile and adult zebrafish (95,96).  365 
 366 
Effects on the heart transcriptome  367 
BPA (100, 1000 µg/L) and MBP (2.5, 25 µg/L) exposures at 5 and 15 dpf resulted in significant 368 
(adjusted p-value < 0.1) differential expression (predominantly down-regulated expression, 369 
compared to solvent controls) in a range of genes governing heart valve development and function 370 
(SI Figures S4-S5; SI Tables S8-S10).  The down-regulation of a range of genes by ER signaling 371 
(via esr1, esr2 and heterodimers of these) has been demonstrated elsewhere in humans and 372 
mammalian models (97,98).  The number of genes affected and the level of effect were greatest at 373 
5 dpf for high-level BPA exposure (371 genes: 329 down-regulated by log2 fold changes of -0.5 374 
to -9), followed by low-level BPA exposure (131 genes: 115 down-regulated by log2 fold changes 375 
of -0.9 to -9) and high-level MBP exposure (127 genes: 101 down-regulated by log2 fold changes 376 
of -2.5 to -9).  There was some overlap between high and low-level BPA exposures at 5 dpf, with 377 
62 genes being common to both treatments, whereas only one gene (elastin microfibril interfacer 378 
3 - emilin3) was common to both MBP treatments at 5 dpf, due in part to the low number of genes 379 
 18 
(8 genes) that were differentially expressed in the low-level MBP exposure (SI Figure S6 - S7).  380 
Collectively however, the genes affected by both BPA and MBP at 5 dpf shared significant 381 
enrichment for molecular pathways concerning i) nuclear receptor and calcium signalling 382 
(estrogen and (para)thyroid), ii) lipid metabolism and  iii) extra-cellular matrix (ECM) interactions 383 
(99) (Figure 4; SI Figure S8; SI Tables S8 – S10). ECM-related pathways comprising collagen and 384 
cartilage formation and organization were particularly prominent for the high-level MBP exposure, 385 
and can be related directly to phenotypic effects on the heart valves observed therein.  ECM 386 
interactions were found to involve Notch signalling (dre04330) and calcium ion binding 387 
(GO:0005509) (SI Table S9) which, along with the afore mentioned pathways (i-iii), have 388 
previously been linked to the progression of calcific aortic valve disease (99,100) (CAVD - 389 
fibrosis, and subsequent calcification and thickening of the aortic valves), which affects up to 13% 390 
of human populations in the western world (99) (see later discussion).  At 15 dpf fewer genes were 391 
differentially expressed compared to 5 dpf.  Although only 5 genes overlapped between time points 392 
for the high-level BPA exposure treatment (SI Figure S7), there was gene set enrichment for 393 
thyroid hormone synthesis (also seen at 5 dpf for MBP) and for estrogen signalling for the 15 dpf 394 
high-level BPA exposure (Figure 4). Both hormone signaling pathways have been highlighted in 395 
mammalian studies on BPA (31,101).  Overall, gene sets from 15 dpf represented pathways 396 
associated with heart function (more so than development), particularly cardiac muscle contraction 397 
(SI Tables S8 – S9).  Four of the 32 genes down-regulated by the high-level BPA exposure: actinin 398 
alpha 3b (actn3b), myosin light chain, phosphorylatable, fast skeletal muscle a (mylpfa), myosin, 399 
heavy polypeptide 2, fast muscle specific (myhz2) and troponin I type 2a (skeletal, fast), tandem 400 
duplicate 4 (tnni2a.4) have previously been identified as potential biomarkers for cardiac disease 401 
in animal models, including zebrafish (102).  Low level BPA exposure at 15 dpf led to the 402 
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differential expression of only gene: apolipoprotein Da, duplicate 2 (apoda.2 transport protein). 403 
The transcriptomic effects of high-level MBP exposure at 15 dpf could not be established due to 404 
problems encountered in sample processing (PCR amplification during library preparation), while 405 
low-level MBP exposure at 15 dpf led to the differential expression of only one (unannotated) gene 406 
(si:dkey-7c18.24) (SI Figure S7, SI Table S8).   407 
 408 
Analysis of TFBS motif enrichment showed that differentially expressed genes in both BPA and 409 
MBP exposures were similarly enriched and were flanked (within 5 kB) by binding sites for 410 
transcription factors associated with estrogen receptor signaling, including: estrogen receptor 2 411 
(esr2); specificity proteins constituting ERE tethering factors (sp1, sp3, sp4); pioneer factors 412 
facilitating ERE binding (foxa1, nfkb2, pbx1, runx1); CAMP responsive element binding proteins 413 
(creb1, creb5) (SI Figure S9, SI Tables S11 – S13).  There was also enrichment for estrogen 414 
receptors (esr1, esr2) beyond proximal promoter regions, up to 50 kB from differentially expressed 415 
genes (SI Table S13).  Examination of these findings versus the established roles of estrogen in 416 
normal (and abnormal) heart valve development indicate plausible links between substantial ERE 417 
activation by BPA and MBP and the observed transcriptomic and phenotypic effects on the heart 418 
valves in our zebrafish.  Endogenous estrogen (17β-estradiol) is known to be protective of the CV 419 
system in later life, which is one of the reasons for hormone replacement therapy in post-420 
menopausal women.  The results of studies on the pathogenesis of CAVD share some similarities 421 
with the findings in our study (in terms of effect pathways) and also show that major risk factors 422 
include polymorphisms of the estrogen receptor (103).  Inactivation of estrogen receptors is 423 
generally associated with increased calcification of the valve leaflets in diseased patients 424 
(104,105).  Empirical studies in mammalian models have shown that estrogen inhibits collagen 425 
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synthesis in rat cardiac fibroblasts (106) and, more specifically, estrogen decreases collagen I and 426 
III gene expression in fibroblasts from female rats (107).  BPA has also been shown to cause sex-427 
specific alterations in gene expression profiles, changes in the composition of the cardiac collagen 428 
extracellular matrix and altered CV function in CD-1 mice (101).  Furthermore, disruption of 429 
collagen in the extracellular matrix has been shown to directly promote valve leaflet calcification 430 
in vitro (108).  Based on these studies it is entirely plausible that the estrogenic action of high-431 
level MBP exposure led to collagen deficiency and valve weakening in our larval zebrafish.  This 432 
preliminary (pre-calcification) condition resembles ‘myxomatous degeneration’ characterized by 433 
collagen degradation and elastic fibre fragmentation, resulting in a “floppy” valve that is prone to 434 
prolapse and regurgitation (109).  As with CAVD, it may be speculated that more progressive 435 
effects of MBP (and BPA) on heart valve development and function may occur in the longer- term 436 
in zebrafish, but this remains to be proven. 437 
 438 
Linking cause and effect 439 
Although estrogen is known to be cardio-protective in later life, inappropriate estrogenic 440 
exposures, including from estrogenic chemicals, in early life can lead to cardiac malformation 441 
(110).  We demonstrate that aqueous exposure to the weak estrogen BPA at 1 and 10 maximum 442 
human maternal-foetal-placental unit concentrations, or its more potent metabolite MBP, at 443 
equivalent potency concentrations, activate estrogen responsive elements (EREs via estrogen 444 
receptor signalling) in the heart valves and alter the expression of a range of genes, including 445 
several governing CV development and function in embryo-larval zebrafish.  BPA and MBP 446 
perturbed similar downstream effect pathways, but only the high-level MBP exposure resulted in 447 
gross phenotypic effects including, malformation of the AV valves, and reduced heart beat and 448 
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blood flow, at 15 dpf.  Our findings provide a substantial chain of evidence, but further work is 449 
required to fully define adverse outcome pathways for the effects of BPA and its metabolites, 450 
including MBP, on heart development and function.  Longer-term studies, including lower level 451 
chemical exposures, are needed, since heart valve formation and remodelling (e.g. AV valve 452 
transitioning from two to four leaflets) is not complete in zebrafish until 35 dpf (62,63) and effects 453 
may not become functionally manifest until in later life.  Vertebrate models with short life spans, 454 
such as zebrafish are highly amenable for this work. 455 
  456 
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FIGURES  457 
 458 
 459 
Figure 1. GFP fluorescence locating and quantifying ERE activation by BPA and MBP in the 460 
heart in embryo-larval zebrafish  461 
Embryo-larval zebrafish at 5 dpf: a) Solvent control; b) 1000 g/L BPA; c) 25 g/L MBP;                 462 
d) Close up of the region of interest showing the heart (encircled).  463 
Fluorescence indicating Estrogen Response Element (ERE) activation was concentrated in the 464 
Atrio-Ventricular (AV) and Ventricular-Bulbous (VB) valves.  465 
  466 
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 467 
         468 
Figure 2. Images of atrio-ventricular (AV) valve leaflets from high-level BPA and MBP exposure 469 
treatments versus solvent controls at 15 days post fertilisation (dpf) 470 
Bright field images a-c are shown at 100 magnification: AV valve leaflets were bent in the high-471 
level MBP exposure.  TEM images d-l are shown at 3000, 6000 and 20000 magnification: The 472 
extra-cellular matrix between the bilayer of valvular cells was narrower and lacked collagen in the 473 
high-level BPA and MBP exposure treatments compared to solvent controls (qualitative 474 
assessment).  Annotations: A = Atrium, V = Ventricle, E = Erythrocytes, Va = Valve leaflet, IS = 475 
Interstitial Space, CF = Collagen Fibres, N = Nucleus, Arrow heads indicate bent AV valve leaflet. 476 




Figure 3. Effects of BPA and MBP exposure on cardiovascular function in zebrafish larvae at 15 480 
days post fertilisation (dpf) 481 
Hatched bar charts (A-B) represent BPA, solid bar charts (C-D) represent MBP.  Data represent 6 482 
individual fish taken randomly from each of 6 separate aquaria (n=6 experimental replicates) per 483 
exposure treatment.  Bar heights represent means, error bars represent 95% confidence intervals. 484 








Figure 4: Gene set enrichment for KEGG pathways in heart tissues from 5 and 15 day old 492 
larval zebrafish in BPA and MBP exposure treatments (versus solvent controls).  493 
Sequence data were generated from hearts pooled from ~30 individuals from each of 4 separate 494 
aquaria (nominally n=4 experimental replicates) per exposure treatment. Enriched pathways 495 
were identified using Enrichr and referenced to the KEGG database (2016). Pathways 496 
highlighted in red boxes are calcific aortic valve disease (CAVD) biomarkers. (Also see enriched 497 
Reactome pathways (in SI Figure S10). 498 
   499 
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ABBREVIATIONS 546 
AIC - Akaike information criterion  547 
AV - atrio-ventricular (valves) 548 
BCF - bio-concentration factor 549 
BPA - bisphenol A 550 
CAVD - calcific aortic valve disease 551 
CV - cardiovascular 552 
DMSO - dimethyl sulfoxide 553 
ECM - extra-cellular matrix 554 
EDC - endocrine disrupting chemical 555 
ER - estrogen receptor 556 
ERE - estrogen response element  557 
GFP - green fluorescent protein 558 
LOQ - limit of quantitation 559 
MBP - 4-methyl-2,4-bis(p-hydroxyphenyl)pent-1-ene 560 
PCR - polymerase chain reaction 561 
ROI - region of interest  562 
SGR - specific growth rate 563 
TEM - transmission electron microscopy 564 
TFBS - transcription factor binding site  565 
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TG - transgenic  566 
VB - ventricular-bulbus (valves) 567 
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